PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-23.20%
Both yoy net incomes decline, with AXSM at -30.95%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
3.49%
D&A growth well above AXSM's 0.82%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
-100.00%
Negative yoy deferred tax while AXSM stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
19.58%
SBC growth while AXSM is negative at -24.18%. John Neff would see competitor possibly controlling share issuance more tightly.
19.36%
Slight usage while AXSM is negative at -106.15%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
55.56%
A yoy AP increase while AXSM is negative at -16.55%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-124.52%
Both reduce yoy usage, with AXSM at -154.96%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
56.31%
Lower 'other non-cash' growth vs. AXSM's 4013.86%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
-16.84%
Both yoy CFO lines are negative, with AXSM at -32.48%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
100.00%
Some CapEx rise while AXSM is negative at -538.67%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We have mild expansions while AXSM is negative at -538.67%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
-594.74%
We cut debt repayment yoy while AXSM is 100.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.